Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5

Drug Metabolism and Disposition

Volumn 37, Issue 2, 2009, Pages 254-258

  Bakken, Gry Vibeke ^a,b   Rudberg, Ida ^a   Christensen, Hege ^b   Molden, Espen ^a,b   Refsum, Helge ^a   Hermann, Monica ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b University Ofoslo   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; QUETIAPINE; SULFOXIDE;

ANIMAL CELL; ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; IN VITRO STUDY; INSECT CELL; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DIBENZOTHIAZEPINES; HUMANS; MICROSOMES; MICROSOMES, LIVER;

HEXAPODA;

EID: 59649128805     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023291     Document Type: Article

References (29)

1. Burk O and Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiede- bergs Arch Pharmacol 369:105-124.
2. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, and Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327.
3. DeVane CL and Nemeroff CB (2001) Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 40:509-522.
4. Donato MT and Castell JV (2003) Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 42:153-178.
5. Ferraresso M, Tirelli A, Ghio L, Grillo P, Martina V, Torresani E, and Edefonti A (2007) Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. Pediatr Transplant 11:296-300.
6. Gefvert O, Bergstriom M, Långstrom B, Lundberg T, Lindstriöm L, and Yates R (1998) Time course of central nervous dopamine-D-2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel (R)) in patients with schizophrenia. Psychopharmacology 135:119-126.
7. Gerlach M, Hudie;nnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement HW, Fegert JM, Wewetzer Ch, and Mehler-Wex C (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72-76.
8. Goldstein JM, Christoph G, Grimm S, Liu JW, Widzowski D, and Brecher M (2007) Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine. The Society of Biological Psychiatry's 62 nd Annual Convention & Scientific Program; 2007 May 17-19; San Diego, CA. Biological Psychiatry, San Diego, CA.
9. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, and Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14:471-478.
10. Grimm SW, Richtand NM, Winter HR, Stams KR, and Reele SB (2006) Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 61:58 -69.
11. Grimm SW, Stams KR, and Bui K (1997) In vitro prediction of potential metabolic drug interactions for Seroquel. Schizophr Res 24:198.
12. Hermann M, Kase ET, Molden E, and Christensen H (2006) Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine A by a statistical experimental design. Curr Drug Metab 7:265-271.
13. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
14. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
15. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, and Roth BL (2008) N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312.
16. Jones HM and Houston JB (2004) Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973-982.
17. Kim KA, Park PW, Lee OJ, Kang DK, and Park JY (2007) Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 47:87-93.
18. Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, and Strandberg T (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525.
19. Klees TM, Sheffels P, Dale O, and Kharasch ED (2005) Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos 33:303-311.
20. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
21. Lamba JK, Lin YS, Schuetz EG, and Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294.
22. Lin SN, Chang Y, Moody DE, and Foltz RL (2004) A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol 28:443-448.
23. Lin YS, Dowling AL, Quigley SD, Farm FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62:162-172.
24. Mclntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, and Konarski JZ (2007) A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmaco- ther 8:1211-1219.
25. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, and Vyas KP (1997) In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
26. Tucker GT, Houston JB, and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 70:103-114.
27. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
28. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita K, and Kamataki T (2003) Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66:2333-2340.
29. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, Boyle G, Law Y, Miller S, Lamba J, et al. (2003) Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 3:477-483.